MENU

Identification of a High Titer Lentiviral Production Alternative to Facilitate Regenerative Medicine Therapies

Speaker
  • Development Engineer / Scientist II, CCRM
    Biography
      Calley Hirsch has been a Development Engineer / Scientist II at CCRM in Toronto for 8 months, where she specializes in upstream lentiviral production and gene delivery technologies. Prior to working at CCRM, Calley was a postdoctoral fellow at the Lunenfeld-Tanenbaum Research Institute in Toronto and MD Anderson Cancer Center in Houston working on pluripotent stem cells and somatic cell reprogramming. Calley received her PhD from the University of Saskatchewan.

    Abstract

    Regenerative medicine therapeutics aimed at restoring normal cell function due to trauma and disease are gaining increasing momentum in clinical trials. For this purpose, lentivirus-based gene delivery is actively being investigated to treat a collection of monogenic and neoplastic diseases. The recent success of CAR-T-cell products further indicate an emerging role for lentiviral therapies, however, scalability and cost-effective production still present manufacturing challenges. To circumvent these problems, transient lentivirus production has been proposed in suspension host cells, yet consistent high titer yields remain difficult to achieve. In this presentation, a lentiviral production screen will be discussed where different cell lines, transfection reagents and media have been assessed to define a baseline process for scalable and cost-effective manufacturing of high titer lentivirus.


    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    Loading Comments...
    Show Resources
    Attendees
    • See more